Bevacizumab-Induced Hypertension Indicative of Better Survival in Glioblastoma
the Cancer Therapy Advisor take:
When compared to normotensive patients with recurrent glioblastoma (GBM), individuals who developed bevacizumab-induced hypertension experienced increased progression-free survival (PFS) and overall survival (OS), according to an article published online in Cancer.
In this study, 82 patients with recurrent GBM were identified as being treated using bevacizumab within the Emory Healthcare system from 2007 through 2012. Of the 82 patients, 30 developed bevacizumab-induced hypertension. The patients were categorized as normotensive or hypertensive based on if their hypertension was drug-induced.
Results showed that the median follow-up period was 19.7 months and the median time to the development of drug-induced hypertension was 21 days.
Furthermore, the median PFS was 2.5 months (95% CI: 1.6, 3.0) for the normotensive group and 6.7 months (95% CI: 4.6, 10.0) for the hypertensive group (PP<0.001).
The study suggests that drug-induced hypertension resulting from treatment with bevacizumab may be a physiologic marker of outcome in individuals with recurrent GBM.
The patients with bevacizumab-induced hypertension displayed greater PFS and OS compared with normotensive patients.
Glioblastoma patients who developed bevacizumab-induced hypertension experienced increased survival.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Immune Signature for Renal Cell Papillary Carcinoma Predicts Outcome
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Adding Chemotherapy to Radiation Post-Radical Cystectomy Improves Survival in Urothelial Carcinoma
- Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer